Skip to main content

Advertisement

SpringerLink
Log in

Inflammation

A new target for aspirin

  • News & Views
  • Published:

From Nature

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hart, F. D., Huskisson, E. C. & Ansell, B. M. in Drug Treatment of the Rheumatic Diseases (ed. Hart, F. D.) 7-60 (ADIS, New York, 1982).

  2. Vane, J. R. Nature New Biol. 231, 232–235 (1971).

    Google Scholar 

  3. Yin, M.-J., Yamamoto, Y. & Gaynor, R. B. Nature 396, 77–80 (1998).

    Article  ADS  CAS  Google Scholar 

  4. Israël, A. Nature 388, 519–521 (1997).

    ADS  PubMed  Google Scholar 

  5. Kopp, E. & Ghosh, S. Science 265, 956–958 (1994).

    Google Scholar 

  6. Rainsford, K. D. Aspirin and the Salicylates (Butterworths, Boston, 1984).

  7. Schwenger, P.et al. Proc. Natl Acad. Sci. USA 94, 2869–2873 (1997).

    Google Scholar 

  8. Davis, R. J. Trends Biochem. Sci. 19, 470–473 (1994).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Rheumatology, Merck Research Laboratories, PO Box 2000, Rahway, 07065-0900, New Jersey, USA

    Edward A. O'Neill

Authors
  1. Edward A. O'Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Neill, E. A new target for aspirin. Nature 396, 15–17 (1998). https://doi.org/10.1038/23810

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/23810

  • Springer Nature Limited

This article is cited by

Search

Navigation